<?xml version='1.0' encoding='utf-8'?>
<document id="29850401"><sentence text="Issues in the management of invasive pulmonary aspergillosis in non-neutropenic patients in the intensive care unit: A role for isavuconazole."><entity charOffset="128-141" id="DDI-PubMed.29850401.s1.e0" text="isavuconazole" /></sentence><sentence text="Almost half of all cases of invasive aspergillosis (IA) occur in the intensive care unit (ICU), with mortality rates of 70-80% for probable or proven cases" /><sentence text=" IA has become a major concern among non-neutropenic patients in the ICU with chronic obstructive pulmonary disease (COPD) but although prompt, appropriate antifungal therapy is crucial, diagnosis in this situation is challenging" /><sentence text=" Criteria for a probable diagnosis in critically ill patients have been proposed to help to expedite therapy" /><sentence text="" /><sentence text="A case of probable invasive pulmonary aspergillosis (IPA) in a non-neutropenic patient admitted to the ICU was used to illustrate potential issues in the diagnostic work-up and management of patients in this setting" /><sentence text="" /><sentence text="A non-neutropenic 69-year-old man with COPD receiving clomipramine was diagnosed in the ICU with probable invasive aspergillosis based on the presence of severe chronic obstructive pulmonary disease, suspected X-linked granulomatous disease, nodular infiltrates and galactogamman positivity on bronchoalveolar lavage (BAL) fluid"><entity charOffset="54-66" id="DDI-PubMed.29850401.s8.e0" text="clomipramine" /></sentence><sentence text=" Voriconazole was unsuitable due to the patient's prolonged QT interval and risk of a drug-drug interaction with clomipramine"><entity charOffset="1-13" id="DDI-PubMed.29850401.s9.e0" text="Voriconazole" /><entity charOffset="113-125" id="DDI-PubMed.29850401.s9.e1" text="clomipramine" /><pair ddi="false" e1="DDI-PubMed.29850401.s9.e0" e2="DDI-PubMed.29850401.s9.e0" /><pair ddi="false" e1="DDI-PubMed.29850401.s9.e0" e2="DDI-PubMed.29850401.s9.e1" /></sentence><sentence text=" Isavuconazole was initiated and the patient's condition improved"><entity charOffset="1-14" id="DDI-PubMed.29850401.s10.e0" text="Isavuconazole" /></sentence><sentence text=" The three-month course of isavuconazole treatment was well-tolerated and resulted in compete recovery of the patient"><entity charOffset="27-40" id="DDI-PubMed.29850401.s11.e0" text="isavuconazole" /></sentence><sentence text="" /><sentence text="Voriconazole is a standard first-line treatment for IA but intravenous therapy is associated with toxicity and the potential for drug-drug interactions"><entity charOffset="0-12" id="DDI-PubMed.29850401.s13.e0" text="Voriconazole" /></sentence><sentence text=" Isavuconazole is another first-line therapy which was effective and safe in the management of this critically ill non-neutropenic patient with baseline QT prolongation and potential drug-drug interactions with voriconazole"><entity charOffset="1-14" id="DDI-PubMed.29850401.s14.e0" text="Isavuconazole" /><entity charOffset="211-223" id="DDI-PubMed.29850401.s14.e1" text="voriconazole" /><pair ddi="false" e1="DDI-PubMed.29850401.s14.e0" e2="DDI-PubMed.29850401.s14.e0" /><pair ddi="false" e1="DDI-PubMed.29850401.s14.e0" e2="DDI-PubMed.29850401.s14.e1" /></sentence><sentence text="" /></document>